TapImmune Inc. (OTCMKTS:TPIV)’s Surge Didn’t Last

Yesterday, TapImmune Inc. (OTCMKTS:TPIV) crashed as abruptly as it had spiked in the previous session, and the reasons for that remain as mysterious as those of its ascent.

Just two days ago, the general opinion on the message boards was that TPIV is oversold and is poised for a breakout. Evidently, that was not the case – not for very long, at least. Why would that be?

Well, when it comes right down to it, TPIV has shown investors no real results to date. The very nature of the company’s current state of developments is discouraging – TPIV is a development stage pharmaceutical OTC Markets penny stock that still has years of research ahead of itself before it can even take a shot at becoming profitable.

The only thing it really has going for it is the fact that it seems to have no difficulty funding its activities. Unfortunately for its investors, that funding comes at the price of massive issuance of common shares.

Some basic due diligence reveals that 23 MILLION out of TPIV‘s 43 million shares outstanding have been issued between Nov. 17, 2014 and July 17, 2015. Investors should punch those numbers into a calculator and see what comes out before loading up on TPIV stock.

They should also think carefully on the fact that the company seems pretty happy with the way it has been doing business, and does not appear at all concerned with finding ways to fund itself without resorting to more dilution.

Since medical trials in general, and cancer research in particular, are expensive endeavors, this most likely means that TPIV will be in need of more funds before long. Suffice it to say, that this does not bode well for TPIV investor value.

Which is one of the reasons investors should be very careful when dealing with TPIV.